Evidence map›Paper›PMID 36599985›Full record

ArticleNature2023

Structural basis of regulated m

Jiazhi Li, Longfei Wang, Quentin Hahn, Radosław P Nowak, Thibault Viennet, Esteban A Orellana, Shourya S Roy Burman, Hong Yue, Moritz Hunkeler, Pietro Fontana and 4 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 110 citations in OpenAlex.

  1. Article
  2. The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026
    Review
  3. Adenosine 5'-Carboxamide-Based Inhibitors of METTL1.ACS medicinal chemistry letters · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Jiazhi Li *Stem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5984-9920
Longfei Wang *Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Quentin HahnStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3510-8364
Radosław P NowakDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0605-0071
Thibault ViennetDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5349-0179
Esteban A OrellanaStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4369-9416
Shourya S Roy BurmanDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9274-9104
Hong YueDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Moritz HunkelerDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0246-1188
Pietro FontanaDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3215-3784
Hao WuDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Haribabu ArthanariDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Eric S FischerDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7337-6306
Richard I GregoryStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA. rgregory@enders.tch.harvard.edu.ORCID http://orcid.org/0000-0001-8090-8673
Boston Children's Hospital · USHarvard University · US

Funding

Role of the Epitranscriptome in CancerR35CA232115 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREGORY, RICHARD I. · 2019 to 2025
$7.2M
Degrading therapeutically important kinases using small moleculesR01CA218278 · NCI · STANFORD UNIVERSITY · PI Eric Sebastian Fischer, NATHANAEL Schiander GRAY · 2019 to 2026
$4.6M
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.R01CA214608 · NCI · DANA-FARBER CANCER INST · PI Eric Sebastian Fischer · 2017 to 2026
$4.0M
NCI NIH HHS HHSN261200800001ENCI NIH HHS R01 CA214608NCI NIH HHS R01 CA218278NCI NIH HHS R35 CA232115
6 · The paper itself

Abstract

Chemical modifications of RNA have key roles in many biological processes

Indexed as

GTP-Binding ProteinsMethyltransferasesRNA Processing, Post-TranscriptionalRNA, TransferBiocatalysisCatalytic DomainGuanosineHumansPhosphorylationSubstrate Specificity7-methylguanosineGTP-Binding ProteinsGuanosineMethyltransferasesMETTL1 protein, humanRNA, TransferWDR4 protein, human

Identifiers

PMID36599985
PMCPMC11179147
OpenAlexW4313483920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.